Work

Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.5_suppl.lba1

Authors: Howard I. Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald De Wit, Peter Mulders, Mohammad Hirmand, Bryan Selby, Johann Sebastian De Bono, for the AFFIRM Investigators

Institutions: Université Paris-Sud, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Erasmus MC, Radboud University Medical Center, Dana-Farber Cancer Institute, Université de Montréal, Charité – Universitätsmedizin Berlin

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2339746554

Cites:

Cited by: 116

Related to: 10